Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

15.78
-0.1800-1.13%
Volume:438.35K
Turnover:6.91M
Market Cap:2.94B
PE:-4.71
High:15.99
Open:15.97
Low:15.63
Close:15.96
52wk High:27.31
52wk Low:13.88
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.66
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:4.19
PE(LYR):-4.54

Loading ...

Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?

Simply Wall St.
·
3 hours ago

Dyne Therapeutics (DYN) After Fresh ACHIEVE Data With Undervalued Narrative Intact

Simply Wall St.
·
Oct 07

Dyne Therapeutics Director Brian S. Posner Acquires $40,000 in Common Shares

Reuters
·
Oct 07

Dyne Therapeutics: Growing Clinical Evidence for z-basivarsen Supports Outperform/Buy Rating and Maintained $40 Price Target

TIPRANKS
·
Sep 30

Dyne Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $32 from $50

THOMSON REUTERS
·
Sep 30

US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB

Reuters
·
Sep 30

Dyne Therapeutics Highlights New ACHIEVE DM1 Trial Data

TIPRANKS
·
Sep 30

Dyne Therapeutics Posts One-Year Phase 1/2 Achieve Data Showing Functional Gains for DYNE-101 in DM1

Reuters
·
Sep 30

Dyne Therapeutics, - Expects Topline Data from Achieve Rec in Q1 2027 with Primary Endpoint Vhot at 6 Months

THOMSON REUTERS
·
Sep 30

Dyne Therapeutics, - Reports Improvement at 6 Months in Vhot with Z-Basivarsen in Dm1

THOMSON REUTERS
·
Sep 30

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 Achieve Trial of Z-Basivarsen (Dyne-101) for Myotonic Dystrophy Type 1 (Dm1)

THOMSON REUTERS
·
Sep 30

Dyne Therapeutics Price Target Maintained with a $47.00/Share by Piper Sandler

Dow Jones
·
Sep 30

Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Sep 29

Dyne Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Sep 29

Dyne Therapeutics Grants New Hires Stock Options for 278,100 Shares, Plus 88,400 Restricted Stock Units

Reuters
·
Sep 18

Dyne Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 18

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 18

Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)

TIPRANKS
·
Sep 11

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says

MT Newswires Live
·
Sep 09

Dyne Therapeutics Price Target Cut to $26.00/Share from $30.00 by Baird

Dow Jones
·
Sep 09